FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial tests the safety, side effects, and best dose of FH-FOLR1 chimeric antigen receptor (CAR) T cells in treating pediatric patients with FOLR1+ acute myeloid leukemia (AML) that has come back after a period of improvement (recurrent) or has not responded to previous treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a FOLR1 on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Chemotherapy drugs, such as fludarabine and cyclophosphamide, are given to a patient before the manufactured FH-FOLR1 CAR T cells are infused back into the patient to assist in the CAR T cell activity in the patient. The trial is evaluating if giving FH-FOLR1 CAR T cell therapy is safe and tolerable for pediatric patients with recurrent or refractory AML.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek do 6 lat
- •Waga co najmniej 7 kilogramów
- •Potwierdzona ostre białaczka szpikowa z markerem FOLR1
- •Powrót białaczki po poprzednim leczeniu lub brak odpowiedzi na wcześniejszą terapię
- •Możliwość znoszenia procedury pobierania komórek krwi
- •Oczekiwana długość życia co najmniej 8 tygodni
- •Dobry ogólny stan zdrowia (wynik Lansky'ego ≥ 50)
- •Znaleziony dawca do przeszczepienia komórek macierzystych
✗ Disqualifies
- •Przerwa w leczeniu chemioterapią poniżej 14 dni przed włączeniem (z wyjątkami)
- •Stosowanie sterydów w ciągu 7 dni przed włączeniem (poza zastępczym dawkowaniem)
- •Stosowanie inhibitorów kinazy tyrozynowej w ciągu 3 dni przed włączeniem
Simplified criteria — AI translation
Trial details
- Maximum age
- 6 Years
- Last updated (source)
- August 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
Seattle, United States
Trial contact
Katherine G. Tarlock, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.